Ananda Developments - Ananda Presentation to LSX Conference 2024
Announcement provided by
Ananda Pharma Plc · ANA14/05/2024 07:00
14 May 2024
ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
Ananda Presentation to LSX Conference 2024
Ananda Developments plc (AQSE: ANA), a company focused on becoming a leading provider of CBD-based medicines for chronic inflammatory pain conditions, recently presented to life science industry leaders at the 10th LSX World Congress in
The LSX World Congress is the leading partnering, strategy and investment event in
Jeremy Sturgess-Smith, Ananda Finance Director, delivered a comprehensive presentation to potential investors and other industry leaders, showcasing the Company's progress in developing patent pending CBD formulations as regulated drugs for chemotherapy induced peripheral pain and endometriosis.
Ananda CEO Melissa Sturgess commented "CBD is a multi-modal molecule and shows great potential for treating people with chronic indications at a time when the NHS is overwhelmed and we have many people unable to go to work. We believe our drug development is happening just at the right time."
The presentation has been uploaded on Ananda's website and can be found via the following link: https://investors.anandadevelopments.com/activity-updates
About Ananda Developments
Ananda is an AQSE-listed company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions.
For further information on the Company visit https://anandadevelopments.com/ or sign up at https://investors.anandadevelopments.com/s/a66906.
|
For more information please contact:
InvestorHub Engage with us directly at Ananda Developments Investor Hub
|
Sign up at https://investors.anandadevelopments.com/s/a66906
|
|
ANANDA DEVELOPMENTS PLC Chief Executive Officer Melissa Sturgess Executive Director Jeremy Sturgess-Smith
|
+44 (0)7463 686 497 ir@anandadevelopments.com |
|
SP ANGEL CORPORATE FINANCE LLP Corporate Finance Richard Morrison Caroline Rowe
|
+44 (0)20 3470 0470 |
|
Corporate Broking Abigail Wayne Rob Rees
|
|
|
Yellow Jersey PR Charles Goodwin Zara McKinlay |
+44 (0)20 3004 9512
|
https://investors.anandadevelopments.com/link/7eXQkr
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
